Journal article
Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels.
- Protic M a Department of Gastroenterology , University Hospital Zvezdara , Belgrade , Serbia.
- Schoepfer A b Division of Gastroenterology and Hepatology , Center Hospitalier Universitaire Vaudois , Lausanne , Switzerland.
- Yawalkar N c Department of Dermatology , University Hospital Bern , Bern , Switzerland.
- Vavricka S d Department of Gastroenterology and Hepatology , Stadtspital Triemli , Zürich , Switzerland.
- Seibold F e Division of Gastroenterology and Hepatology , University Hospital Fribourg , Fribourg , Switzerland.
- 2016-08-19
Published in:
- Scandinavian journal of gastroenterology. - 2016
Crohn’s disease
Psoriasis
adalimumab
certolizumab pegol
inflammatory bowel disease
infliximab
ulcerative colitis
Adalimumab
Adolescent
Adult
Case-Control Studies
Certolizumab Pegol
Female
Humans
Inflammatory Bowel Diseases
Infliximab
Logistic Models
Male
Multivariate Analysis
Psoriasis
Switzerland
Treatment Outcome
Tumor Necrosis Factor-alpha
Young Adult
English
BACKGROUND
The cause of anti-TNF-induced psoriasis is still unknown.
OBJECTIVE
We aimed to evaluate if the appearance of psoriasis under anti-TNF therapy is associated with anti-TNF antibody levels and TNF-antagonist trough levels.
METHODS
In this case-control study we identified 23 patients (21 with Crohn's disease [CD], two with ulcerative colitis [UC]) who developed psoriasis under infliximab (IFX, n = 20), adalimumab (ADA, n = 2), and certolizumab pegol (CZP, n= 1) and compared them regarding the anti-TNF-antagonist antibody levels with 85 IBD patients (72 with CD, 13 with UC) on anti-TNF therapy without psoriasis.
RESULTS
Median disease duration was not different between the two groups (7 years in the group with psoriasis under TNF-antagonists vs. 10 years in the control group, p = 0.072). No patient from the psoriasis group had antibodies against TNF-antagonists compared to 10.6% in the control group (p = 0.103). No difference was found in IFX trough levels in the group of patients with psoriasis compared to the control group (2.6 μg/mL [IQR 0.9-5.5] vs. 3.4 μg/mL [IQR 1.4-8.1], p = 0.573). TNF-antagonist therapy could be continued in 91.3% of patients with TNF-antagonist related psoriasis and most patients responded to topical therapies.
CONCLUSION
Anti-TNF-induced psoriasis seems to be independent of anti-TNF antibodies and trough levels. Interruption of Anti-TNF therapy is rarely necessary.
The cause of anti-TNF-induced psoriasis is still unknown.
OBJECTIVE
We aimed to evaluate if the appearance of psoriasis under anti-TNF therapy is associated with anti-TNF antibody levels and TNF-antagonist trough levels.
METHODS
In this case-control study we identified 23 patients (21 with Crohn's disease [CD], two with ulcerative colitis [UC]) who developed psoriasis under infliximab (IFX, n = 20), adalimumab (ADA, n = 2), and certolizumab pegol (CZP, n= 1) and compared them regarding the anti-TNF-antagonist antibody levels with 85 IBD patients (72 with CD, 13 with UC) on anti-TNF therapy without psoriasis.
RESULTS
Median disease duration was not different between the two groups (7 years in the group with psoriasis under TNF-antagonists vs. 10 years in the control group, p = 0.072). No patient from the psoriasis group had antibodies against TNF-antagonists compared to 10.6% in the control group (p = 0.103). No difference was found in IFX trough levels in the group of patients with psoriasis compared to the control group (2.6 μg/mL [IQR 0.9-5.5] vs. 3.4 μg/mL [IQR 1.4-8.1], p = 0.573). TNF-antagonist therapy could be continued in 91.3% of patients with TNF-antagonist related psoriasis and most patients responded to topical therapies.
CONCLUSION
Anti-TNF-induced psoriasis seems to be independent of anti-TNF antibodies and trough levels. Interruption of Anti-TNF therapy is rarely necessary.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1080/00365521.2016.1218541
- PMID 27534974
- Persistent URL
- https://sonar.ch/global/documents/367
Statistics
Document views: 24
File downloads: